. 2018 Mar 7;18:161. doi: 10.1186/s12913-018-2965-5

Table 2.

Medicare allowed costs during follow-up – overall HBPC participants/matched controls

		N	Total cost	RX cost (% total)	IP cost (% total)	OP cost (% total)	Savings, 95% CI, p-value
12 months	HBPC	210	$28,621	$4937 (17.24%)	$9783 (34.18%)	$7462 (26.07%)	($2933) ($7672), $1806 p = 0.225
12 months	Ctrl	210	$25,688	$4677 (18.21%)	$10,573 (41.15%)	$4576 (17.81%)	($2933) ($7672), $1806 p = 0.225
24 months	HBPC	210	$39,738	$6798 (17.11%)	$12,558 (31.60%)	$11,003 (27.69%)	$8620 $1959, $15,281 p = 0.011
24 months	Ctrl	210	$48,358	$8600 (17.78%)	$19,859 (41.06%)	$8422 (17.41%)	$8620 $1959, $15,281 p = 0.011

Table 2 provides patterns of medical costs and savings for the matched HBPC participant and control samples at 12 and 24 months. HBPC participants show greater expenditure than matched controls at 12 months. At 24 months, this has reversed, and HBPC participants show medical cost savings driven primarily by reductions in in-patient costs